UCB agrees to pay $34m in anti-epileptic drug case
The settlement would include both the US DOJ and the Attorneys General of many of the US, in resolution of two False Claims Act qui tam actions initiated
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.